Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: onr:"swepub:oai:DiVA.org:uu-469229" > Risk classification...

1 av 1
Föregående post
Nästa post
Till träfflistan

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		10434naa a2200997 4500
001		oai:DiVA.org:uu-469229
003		SwePub
008		220308s2022 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
009		oai:prod.swepub.kib.ki.se:148882571
024	7	a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4692292 URI
024	7	a https://doi.org/10.1182/bloodadvances.20210048812 DOI
024	7	a http://kipublications.ki.se/Default.aspx?queryparsed=id:1488825712 URI
040		a (SwePub)uud (SwePub)ki
041		a engb eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Menghrajani, Kamalu Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA.4 aut
245	1 0	a Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
264		c 2022-02-01
264	1	b American Society of Hematology,c 2022
338		a print2 rdacarrier
520		a Little is known about whether risk classification at diagnosis predicts post-hematopoietic cell transplantation (HCT) outcomes in patients with acute myeloid leukemia (AML). We evaluated 8709 patients with AML from the CIBMTR database, and after selection and manual curation of the cytogenetics data, 3779 patients in first complete remission were included in the final analysis: 2384 with intermediate-risk, 969 with adverse-risk, and 426 with KMT2A-rearranged disease. An adjusted multivariable analysis detected an increased risk of relapse for patients with KMT2A-rearranged or adverse-risk AML as compared to those with intermediate-risk disease (hazards ratio [HR], 1.27; P = .01; HR, 1.71; P < .001, respectively). Leukemia-free survival was similar for patients with KMT2A rearrangement or adverse risk (HR, 1.26; P = .002, and HR, 1.47; P < .001), as was overall survival (HR, 1.32; P < .001, and HR, 1.45; P < .001). No differences in outcome were detected when patients were stratified by KMT2A fusion partner. This study is the largest conducted to date on post-HCT outcomes in AML, with manually curated cytogenetics used for risk stratification. Our work demonstrates that risk classification at diagnosis remains predictive of post-HCT outcomes in AML. It also highlights the critical need to develop novel treatment strategies for patients with KMT2A-rearranged and adverse-risk disease.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
700	1	a Gomez-Arteaga, Alexandrau Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA.4 aut
700	1	a Madero-Marroquin, Rafaelu Icahn Sch Med, Dept Med, Mt Sinai St Luke, New York, NY USA.4 aut
700	1	a Zhang, Mei-Jieu Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Inst Hlth & Equ, Div Biostat, Milwaukee, WI 53226 USA.4 aut
700	1	a Bo-Subait, Khalidu Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.4 aut
700	1	a Sanchez, Jonathanu Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.4 aut
700	1	a Wang, Hai-Linu Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.4 aut
700	1	a Aljurf, Mahmoudu King Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riyadh, Saudi Arabia.4 aut
700	1	a Assal, Ameru Columbia Univ Irving Med Ctr, Dept Med, Bone Marrow Transplant & Cell Therapy Program, New York, NY USA.4 aut
700	1	a Bacher, Vera Ulrikeu Univ Bern, Bern Univ Hosp, Dept Hematol, Inselspital, Bern, Switzerland.4 aut
700	1	a Badawy, Sherif M.u Ann & Robert H Lurie Childrens Hosp Chicago, Div Hematol Oncol & Stem Cell Transplant, Chicago, IL 60611 USA.;Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA.4 aut
700	1	a Bejanyan, Nelliu H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA.4 aut
700	1	a Bhatt, Vijaya Raju Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE USA.4 aut
700	1	a Bredeson, Christopheru Ottawa Hosp, Blood & Marrow Transplant Program, Ottawa, ON, Canada.;Ottawa Hosp Res Inst, Ottawa, ON, Canada.4 aut
700	1	a Byrne, Michaelu Vanderbilt Univ, Div Hematol & Oncol, Med Ctr, Nashville, TN USA.4 aut
700	1	a Castillo, Paulu UF Hlth Shands Childrens Hosp, Dept Pediat Coll Med, Div Hematol & Oncol, Gainesville, FL USA.4 aut
700	1	a Cerny, Janu Univ Massachusetts, Med Ctr, Dept Med, Div Hematol Oncol, Worcester, MA USA.4 aut
700	1	a Chhabra, Saurabhu Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, Div Hematol Oncol, Milwaukee, WI 53226 USA.4 aut
700	1	a Ciurea, Stefan Octavianu Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Div Canc Med, Houston, TX 77030 USA.4 aut
700	1	a DeFilipp, Zachariahu Massachusetts Gen Hosp, Blood & Marrow Transplant Program, Boston, MA 02114 USA.4 aut
700	1	a Farhadfar, Noshau Univ Florida, Coll Med, Div Hematol Oncol, Gainesville, FL USA.4 aut
700	1	a Gadalla, Shahinazu NCI, Div Canc Epidemiol & Genet, Clin Genet Branch, NIH, Rockville, MD USA.4 aut
700	1	a Gale, Robert Peteru Imperial Coll London, Haematol Res Ctr, Dept Immunol & Inflammat, London, England.4 aut
700	1	a Ganguly, Siddharthau Univ Kansas Hlth Syst, Div Hematol Malignancy & Cellular Therapeut, Kansas City, KS USA.4 aut
700	1	a Gowda, Lohithu Yale Univ, Sch Med, Dept Med,Sect Hematol, Yale Comprehens Canc Ctr,Yale New Haven Hosp, New Haven, CT 06510 USA.4 aut
700	1	a Grunwald, Michael R.u Atrium Hlth, Dept Hematol Oncol & Blood Disorders, Levine Canc Inst, Charlotte, NC USA.4 aut
700	1	a Hashmi, Shahrukhu Mayo Clin, Dept Internal Med, Rochester, MN USA.;King Faisal Specialist Hosp & Res Ctr, Oncol Ctr, Riyadh, Saudi Arabia.4 aut
700	1	a Hildebrandt, Gerhardu Univ Kentucky, Markey Canc Ctr, Lexington, KY USA.4 aut
700	1	a Kanakry, Christopher G.u NCI, Expt Transplantat & Immunol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.4 aut
700	1	a Kansagra, Ankitu UT Southwestern Med Ctr, Blood & Marrow Transplant Program, Dallas, TX USA.4 aut
700	1	a Khimani, Farhadu H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.4 aut
700	1	a Krem, Maxwellu Univ Kentucky, Coll Med, Markey Canc Ctr, Lexington, KY USA.4 aut
700	1	a Lazarus, Hillardu Case Western Reserve Univ, Univ Hosp Case Med Ctr, Dept Med, Cleveland, OH 44106 USA.;Case Western Reserve Univ, Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.4 aut
700	1	a Liu, Hongtaou Univ Chicago Med, Sect Hematol Oncol, Chicago, IL USA.4 aut
700	1	a Martino, Rodrigou Hosp Santa Creu & Sant Pau, Div Clin Hematol, Barcelona, Spain.4 aut
700	1	a Michelis, Fotios, Vu Princess Margaret Canc Ctr, Allogene Blood & Marrow Transplant Program, Toronto, ON, Canada.4 aut
700	1	a Nathan, Sunitau Rush Univ, Med Ctr, Sect Bone Marrow Transplant & Cell Therapy, Chicago, IL 60612 USA.4 aut
700	1	a Nishihori, Taigau Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE USA.4 aut
700	1	a Olsson, Richardu Uppsala universitet,Institutionen för medicinsk cellbiologi,Centrum för klinisk forskning i Sörmland (CKFD),Hematologi,Karolinska Inst, Dept Lab Med, Stockholm, Sweden.4 aut0 (Swepub:uu)riols677
700	1	a Reshef, Ranu Columbia Univ, Med Ctr, Blood & Marrow Transplantat Program, New York, NY USA.;Columbia Univ, Columbia Ctr Translat Immunol, Med Ctr, New York, NY USA.4 aut
700	1	a Rizzieri, Davidu Duke Univ, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA.4 aut
700	1	a Rowe, Jacob M.u Shaare Zedek Med Ctr, Dept Hematol, Jerusalem, Israel.4 aut
700	1	a Savani, Bipin N.u Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA.4 aut
700	1	a Seo, Sachikou Dokkyo Med Univ, Dept Hematol & Oncol, Mibu, Tochigi, Japan.4 aut
700	1	a Sharma, Akshayu St Jude Childrens Res Hosp, Dept Bone Marrow Transplantat & Cellular Therapy, 332 N Lauderdale St, Memphis, TN 38105 USA.4 aut
700	1	a Solh, Melhemu Northside Hosp, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA.4 aut
700	1	a Ustun, Celalettinu Rush Univ, Med Ctr, Hematol Oncol & Cell Therapy, Chicago, IL 60612 USA.4 aut
700	1	a Verdonck, Leo F.u Isala Clin, Dept Hematol & Oncol, Zwolle, Netherlands.4 aut
700	1	a Hourigan, Christopheru NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA.4 aut
700	1	a Sandmaier, Brendau Univ Washington, Div Med Oncol, Seattle, WA 98195 USA.;Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.4 aut
700	1	a Litzow, Marku Mayo Clin Rochester, Div Hematol & Transplant Ctr, Rochester, MN USA.4 aut
700	1	a Kebriaei, Partowu Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Div Canc Med, Houston, TX 77030 USA.4 aut
700	1	a Weisdorf, Danielu Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Box 736 UMHC, Minneapolis, MN 55455 USA.4 aut
700	1	a Zhang, Yanmingu Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA.4 aut
700	1	a Tallman, Martin S.u Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA.;Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA.4 aut
700	1	a Saber, Waelu Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.4 aut
710	2	a Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA.b Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA.4 org
773	0	t Blood Advancesd : American Society of Hematologyg 6:3, s. 828-847q 6:3<828-847x 2473-9529x 2473-9537
856	4	u https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2021004881/1823739/bloodadvances.2021004881.pdf
856	4 8	u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-469229
856	4 8	u https://doi.org/10.1182/bloodadvances.2021004881
856	4 8	u http://kipublications.ki.se/Default.aspx?queryparsed=id:148882571

Hitta via bibliotek

Blood Advances (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

1 av 1
Föregående post
Nästa post
Till träfflistan

Hitta mer i SwePub

Av författaren/redakt...: Menghrajani, Kam ...; Gomez-Arteaga, A ...; Madero-Marroquin ...; Zhang, Mei-Jie; Bo-Subait, Khali ...; Sanchez, Jonatha ...; visa fler...; Wang, Hai-Lin; Aljurf, Mahmoud; Assal, Amer; Bacher, Vera Ulr ...; Badawy, Sherif M ...; Bejanyan, Nelli; Bhatt, Vijaya Ra ...; Bredeson, Christ ...; Byrne, Michael; Castillo, Paul; Cerny, Jan; Chhabra, Saurabh; Ciurea, Stefan O ...; DeFilipp, Zachar ...; Farhadfar, Nosha; Gadalla, Shahina ...; Gale, Robert Pet ...; Ganguly, Siddhar ...; Gowda, Lohith; Grunwald, Michae ...; Hashmi, Shahrukh; Hildebrandt, Ger ...; Kanakry, Christo ...; Kansagra, Ankit; Khimani, Farhad; Krem, Maxwell; Lazarus, Hillard; Liu, Hongtao; Martino, Rodrigo; Michelis, Fotios ...; Nathan, Sunita; Nishihori, Taiga; Olsson, Richard; Reshef, Ran; Rizzieri, David; Rowe, Jacob M.; Savani, Bipin N.; Seo, Sachiko; Sharma, Akshay; Solh, Melhem; Ustun, Celaletti ...; Verdonck, Leo F.; Hourigan, Christ ...; Sandmaier, Brend ...; Litzow, Mark; Kebriaei, Partow; Weisdorf, Daniel; Zhang, Yanming; Tallman, Martin ...; Saber, Wael; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Hematologi

Artiklar i publikationen: Blood Advances

Av lärosätet: Uppsala universitet; Karolinska Institutet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se